Evidence map›Paper›PMID 42663723›Full record

ArticleMolecular biology reports2026

circBIRC6 regulates cisplatin resistance of choroidal melanoma via positively modulating ERK by sponging miR-503-3p.

Wei Li, Jiaojiao Zhang, Qian Tan, Xiao Han, Ning Xie, Gaohua Liang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei LiDepartment of Ophthalmology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Guangdong, 518000, Shenzhen, China.
Jiaojiao ZhangDepartment of Ophthalmology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Guangdong, 518000, Shenzhen, China.
Qian TanDepartment of Ophthalmology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Guangdong, 518000, Shenzhen, China.
Xiao HanDepartment of Ophthalmology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Guangdong, 518000, Shenzhen, China.
Ning XieDepartment of Ophthalmology, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Guangdong, 518000, Shenzhen, China. ningxiedr@yeah.net.
Gaohua LiangDepartment of Ophthalmology, The Affiliated Hospital of Youjiang Medical University for Nationalities, No.18 Zhongshan Road, Guangxi, 53300, Baise, China.

Funding

Guangdong Medical Science and Technology Research Fund Project B2018139The First Batch of High-level Talent Scientific Research Projects of the Affiliated Hospital of Youjiang Medical University for Nationalities in 2019 Contract No. R20196340; Contract No. Y20196304the Natural Science Foundation of Guangxi 2020GXNSFAA259054
6 · The paper itself

Abstract

purposecircRNA plays a key regulatory role in various human tumors. This study was carried out to investigate the molecular mechanism of circBIRC6 in regulating cisplatin (DDP) resistance in choroidal melanoma.

methodsThe expression of circBIRC6 in choroidal melanoma tissues and cells (MUM-2B, MUM-2B/DDP) were detected by RT-qPCR. The roles of circBIRC6 in DDP resistance in choroidal melanoma were analyzed by loss-of-function and overexpression experiments. The DDP inhibition rate was detected by MTT assay. Western blotting was used to analyze the protein levels of P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1), and ERK1/2 (ERK1/MAPK3 and ERK2/MAPK1). The relationship between circBIRC6, miR-503-3p and ERK1/2 was analyzed by CircRIP and dual-luciferase reporter assays.

resultscircBIRC6 was significantly upregulated in choroidal melanoma tissues and DDP-resistant MUM-2B cells. CircBIRC6 regulated DDP resistance in choroidal melanoma cells by binding to miR-503-3p. ERK1/2 was directly targeted by miR-503-3p, and ERK1/2 inhibited miR-503-3p-induced DDP resistance. Finally, the expression of circBIRC6 was positively correlated with ERK1/2, and it was verified that circBIRC6 regulated ERK1/2 by targeting miR-503-3p.

conclusionsCircBIRC6 regulated the expression of ERK1/2 in choroidal melanoma cells and DDP resistance via miR-503-3p. These results suggested that knockdown of circBIRC6 may provide an effective treatment strategy for DDP-resistant choroidal melanoma.

Indexed as

Choroid NeoplasmsCisplatinDrug Resistance, NeoplasmMelanomaMicroRNAsRNA, CircularCell Line, TumorGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemCisplatinMicroRNAsMIRN503 microRNA, humanRNA, CircularChoroidal melanomacircBIRC6CisplatinERK1/2miR-503-3p

Identifiers

PMID42663723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.